William E. Porter, M.D.

Page 1

MDL NO. 2326

IN THE UNITED STATES DISTRICT COURT

FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA

CHARLESTON DIVISION

IN RE: BOSTON SCIENTIFIC CORP.,

PELVIC REPAIR SYSTEM

PRODUCTS LIABILITY LITIGATION

THIS DOCUMENT RELATES TO:

ALL WAVE 1 AND 2 CASES IN MDL NO. 2326

VIDEOTAPED DEPOSITION OF
WILLIAM E. PORTER M.D.
Tuesday, December 2, 2014
Charlotte, North Carolina
4:29 p.m.

Reported by: Karen K. Kidwell, RMR, CRR, CLR GOLKOW TECHNOLOGIES, INC.

877.370.3377 ph|917.591.5672 fax deps@golkow.com

EXHIBIT

```
Page 234
1
      BY MS. PACKER:
2
                 And do you agree with this statement?
            Q.
 3
                 MR. PRICE: Object to form.
                               The first five, four
                 THE WITNESS:
 5
           sentences -- or four lines?
 6
      BY MS. PACKER:
7
                 Well, you read it in the past, correct?
            0.
 8
            Α.
                 I have to reread everything.
9
      generality --
10
            0.
                 Sure.
11
                 -- I think slings have the role for
            Α.
12
      treating stress urinary incontinence, correct.
13
                 Do you agree with this introductory
14
      language that says, "The polypropylene mesh
      mid-urethral sling is the recognized worldwide
15
16
      standard of care for the surgical treatment of stress
17
      urinary incontinence. The procedure is safe,
      effective and has improved the quality of life for
18
     millions of women"?
19
20
            Α.
                 I agree with that, yes.
21
            0.
                 And do you agree with the statement
22
      that -- turning the page now, that "Polypropylene
23
      material has been used in most surgical specialties,
24
      including general surgery, cardiovascular surgery,
25
      transplant surgery, ophthalmology, otolaryngology,
```

```
Page 237
1
     BY MS. PACKER:
 2
            Q.
                 Do you agree that "A broad evidence base,
 3
      including high-quality scientific papers in medical
4
      journals in the U.S. and the world supports the use
5
      of the MUS as a treatment for SUI"?
                 MR. PRICE: Object to form.
7
                 THE WITNESS:
                               Yes.
8
     BY MS. PACKER:
9
            0.
                 And "MUS" means "mid-urethral sling"?
10
            A. Correct.
11
                 And "SUI" means "stress urinary
            0.
12
      incontinence." Is that correct?
13
            Α.
                 Correct.
14
                 Do you agree with the statement that "Full
            Q.
15
      length mid-urethral slings both retropubic and
16
      transobturator have been extensively studied, are
17
      safe and effective relative to other treatment
18
      options and remain the leading treatment option and
19
      currently gold standard for stress incontinence
20
      surgery"?
21
                 Yes.
            Α.
22
                 MR. PRICE: Object to form.
23
      BY MS. PACKER:
24
                 Are you familiar with the AUGS
25
      statement -- position statement on restriction of
```